Abstract
Peripheral arterial disease is highly prevalent in the elderly and in the subjects with cardiovascular risk factors such as diabetes. Approximately 2% to 4% of those affected with peripheral arterial disease commonly complain of intermittent claudication. Cilostazol, a type III phosphodiesterase inhibitor, is the only Food and Drug Administration-approved drug for the treatment of intermittent claudication. Cilostazol has been shown to be beneficial for the improvement of pain-free walking distance in patients with intermittent claudication in a series of randomized clinical trials. However, the underlying mechanism how cilostazol improved intermittent claudication symptoms is still unclear. In this study, the effect of cilostazol on ischemic leg was investigated in mouse ischemic hindlimb model. Administration of cilostazol significantly increased the expression of hepatocyte growth factor (HGF), vascular endothelial growth factor, angiopoietin-1, and peroxisome proliferator-activated receptor-γ in vasculature. The capillary density in ischemic leg was also significantly increased in cilostazol treatment group when compared with control and aspirin treatment group. However, an increase in capillary density and the expression o...Continue Reading
References
Feb 6, 1992·The New England Journal of Medicine·M H CriquiD Browner
Jun 1, 1991·International Journal of Epidemiology·F G FowkesR J Prescott
Dec 1, 1996·International Journal of Epidemiology·G C LengC V Ruckley
Sep 23, 1997·Diabetologia·R MorishitaT Ogihara
Jan 21, 2000·Hypertension·S HayashiT Ogihara
Nov 7, 2000·The American Journal of Medicine·D L DawsonD E Strandness
Aug 3, 2001·Diabetologia·M AokiT Ogihara
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Therese M Chapman, Karen L Goa
Sep 24, 2004·Current Drug Targets. Cardiovascular & Haematological Disorders·G MelilloM C Capogrossi
Jan 8, 2005·Circulation Research·Jeong-Ki MinYoung-Guen Kwon
Oct 26, 2005·Circulation·John S DouglasUNKNOWN Cilostazol for Restenosis Trial (CREST) Investigators
Nov 18, 2005·Journal of the American Society of Nephrology : JASN·Yingjian LiYouhua Liu
Mar 21, 2006·Atherosclerosis·Ayako HashimotoToyoki Mori
Apr 28, 2006·Blood·Hanako KobayashiPengnian Charles Lin
Dec 5, 2006·European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery·L NorgrenKenneth Rosenfield
Mar 22, 2008·Atherosclerosis·So Youn ParkKi Whan Hong
Jul 22, 2008·Canadian Journal of Physiology and Pharmacology·Furong WangJiajun Zhao
Jan 10, 2009·Vascular and Endovascular Surgery·Mark E O'DonnellC V Soong
Feb 18, 2009·The Journal of Pharmacology and Experimental Therapeutics·So Youn ParkKi Whan Hong
Aug 29, 2009·Circulation Research·Fumihiro SanadaRyuichi Morishita
Sep 1, 2009·BMC Cardiovascular Disorders·I VaartjesM L Bots
Apr 5, 2012·International Journal of Cardiology·Federico BiscettiAndrea Flex
Jan 11, 2013·Physiological Reviews·Hang YinMichael A Rudnicki
Jan 26, 2013·International Journal of Cardiology·Keun-Ho ParkJung Chaee Kang
Aug 7, 2013·Lancet·F Gerald R FowkesMichael H Criqui
May 26, 2015·Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry·Fumihiro SanadaRyuichi Morishita
Citations
Oct 21, 2016·Journal of Endocrinological Investigation·A M IsidoriD Fiore
Aug 26, 2016·Journal of Medicinal Chemistry·Robert B CameronRick G Schnellmann
Mar 10, 2017·Scientific Reports·Jun MuratsuRyuichi Morishita
Oct 19, 2019·Cardiovascular Engineering and Technology·Jiangjin LiYafei Shi
Sep 29, 2017·Vascular Specialist International·George Galyfos, Argyri Sianou
Nov 2, 2018·PloS One·Christopher LambersMichael Roth
May 18, 2017·Oncotarget·Jaspal GargThomas Wieland
Jan 4, 2018·Oncotarget·I-Chih ChenTing-Hsing Chao
Jul 23, 2020·Acta Pharmacologica Sinica·Yu-Meng MiaoYue Dai
Oct 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Hong S LuAlan Daugherty
Jul 1, 2020·Annals of Vascular Diseases·Fumihiro SanadaRyuichi Morishita
Dec 29, 2020·Clinical Therapeutics·Chiu-Yang LeeShing-Jong Lin
Jan 23, 2021·American Journal of Physiology. Heart and Circulatory Physiology·Kenichiro ShimataniYoshiki Sawa
Oct 13, 2019·Current Medicinal Chemistry·Agnieszka JankowskaGrażyna Chłoń-Rzepa
Oct 22, 2021·Journal of Clinical Pharmacology·Antonis A ManolisAntonis S Manolis
Dec 1, 2021·Pharmaceutical Biology·Quanquan ShenFei Han